NYSE:LLY 9 August 2025 - 25 February 2026

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
·····

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist

Structure Therapeutics shares climbed 5.3% to $38.79 in late New York trading Thursday, with no new company release in the past two days. The move followed Eli Lilly’s report of strong weight-loss data for its obesity drug, which kept focus on the sector. Structure’s aleniglipron showed 16.3% placebo-adjusted mean weight loss at 44 weeks in Phase 2. Monashee Investment Management trimmed its stake in the first quarter, SEC filings show.
May 21, 2026
Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan
·····

Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan

Eli Lilly shares fell 1.6% to $1,042.15 Tuesday, then edged up 0.1% after hours, following FDA clearance of a four-dose Zepbound KwikPen for weight loss. The new device will cost $299 per month for cash customers. Novo Nordisk announced it will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027. Investors weighed pricing moves and clinical trial results as competition intensified.
February 25, 2026
Eli Lilly stock slips even after Zepbound-Taltz psoriasis data; investors eye what’s next for LLY
····

Eli Lilly stock slips even after Zepbound-Taltz psoriasis data; investors eye what’s next for LLY

Eli Lilly shares dropped 1.8% to $1,017.86 by late morning Wednesday, underperforming the S&P 500. The company reported late-stage trial data showing its Zepbound-Taltz combination improved skin and weight outcomes in psoriasis patients versus Taltz alone. Investors remain cautious about Lilly’s ability to expand use-cases and defend pricing as competition increases.
February 18, 2026
Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
········

Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions

Novartis said AI reduced trial site selection for a 14,000-person Leqvio study to a two-hour meeting. Drugmakers report AI is cutting weeks from clinical trial logistics and regulatory paperwork. AstraZeneca and others still face challenges managing thousands of regulatory documents. Analysts say it may take one to three years before investors see the full impact on drug development timelines.
January 26, 2026
Groundbreaking treatments - super crops - and a revolution in green technology
·········

Biotech 2025: Breakthrough Cures, Super Crops, and a Green Tech Revolution

The global biotech market is set to rise from $483 billion in 2024 to $546 billion in 2025. Casgevy, the first CRISPR-based gene therapy for sickle cell disease, will reach patients in 2025. Novo Nordisk and Eli Lilly invested billions to resolve U.S. shortages of GLP-1 drugs. Over 60% of new crop varieties in 2025 use advanced gene-editing, not traditional breeding.
August 9, 2025